EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Incidence and outcomes of FGFR inhibitor-associated retinopathy of patients treated with oral erdafitinib across the clinical trial program

Anne O'Hagan, Arlene Siefker-Radtke, Yohann Loriot, Kris Deprince, Lauren Crow, Michal Laron, Ron Adelman, Hussein Sweiti, Spyros Triantos iD

The Oncologist · 06.06.2026 · 31 (7)

DOI: 10.1093/oncolo/oyag174 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 13.05.2026. Verfasst von Anne O'Hagan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Johnson & Johnson, Spring House, PA, 19477, United States. Hauptthemen laut MEDLINE: Pyrazoles, Quinoxalines, Receptors, Fibroblast Growth Factor, Retinal Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson & Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fibroblast growth factor receptors inhibitors (FGFRi) are approved treatments for various malignancies. FGFRi-associated retinopathy is a class effect of FGFRi, including erdafitinib, pemigatinib, infigratinib, and rogaratinib. Patients and Methods We summarized FGFRi-associated retinopathy with erdafitinib across 5 clinical studies in patients with metastatic urothelial cancer (mUC pooled studies) and one study in patients with advanced solid tumors (RAGNAR). We also present changes in visual acuity, retinal pigment epithelial elevation, and subretinal fluid in RAGNAR.

Results

One hundred and three (21.5%) of 479 patients in the mUC pooled studies and 43/314 (13.7%) patients in RAGNAR experienced FGFRi-associated retinopathy. Most FGFRi-associated retinopathy were Grade 1/2 events. Grade 3 FGFRi-associated retinopathy were infrequent (mUC pooled studies, 11/479 [2.3%]; RAGNAR, 3/314 [1.0%]). No Grade 4 events occurred. Most FGFRi-associated retinopathy events (mUC pooled studies, 81/103 [78.6%]; RAGNAR, 30/43 [70.0%]) occurred within 90 days of treatment initiation and were managed with erdafitinib dose interruption (mUC pooled studies, 41/479 [8.6%]; RAGNAR, 23/314 [7.3%]) or reduction (mUC pooled studies, 58/479 [12.1%]; RAGNAR, 21/314 [6.7%]); few required treatment discontinuation (mUC pooled studies, 14/479 [2.9%]; RAGNAR, 3/314 [1.0%]). By the data cutoff, 63.1% (65/103) patients in the mUC pooled studies and 65.1% (28/43) patients in RAGNAR had their FGFRi-associated retinopathy events resolve. Most unresolved FGFRi-associated retinopathy events were persistent Grade 1 events. In RAGNAR, 92.0% of patients had their visual acuity return to baseline and 78.5% of patients had their retinal pigment epithelial elevation resolve.

Conclusions

FGFRi-associated retinopathy with erdafitinib can be managed with dose reductions, interruptions, or discontinuations. Proactive collaboration between oncologists and ophthalmologists is required to ensure that erdafitinib delivers clinical benefit to patients while managing their potential adverse symptoms of FGFRi-associated retinopathy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazolesQuinoxalinesReceptors, Fibroblast Growth FactorRetinal DiseasesProtein Kinase InhibitorsHumansFemaleMaleAgedMiddle AgedAdministration, Oral

Stichwörter der Autor:innen

erdafitinibfibroblast growth factor receptorsretinopathy

Substanzen

erdafitinibPyrazolesQuinoxalinesReceptors, Fibroblast Growth FactorProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Johnson & Johnson, Spring House, PA, 19477, United States.
  • The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, United States.
  • Institut Gustave Roussy, Villejuif, 94805, France.
  • Johnson & Johnson, Beerse, 2340, Belgium.
  • Johnson & Johnson, Milpitas, CA, 95054, United States.
  • Mayo Clinic, Jacksonville, FL, 32224, United States.

ORCID-Profile: Spyros Triantos

Förderung

  • Johnson & Johnson

Zitieren

APA

O'Hagan, A., Siefker-Radtke, A., Loriot, Y., Deprince, K., Crow, L., Laron, M., Adelman, R., Sweiti, H., & Triantos, S. (2026). Incidence and outcomes of FGFR inhibitor-associated retinopathy of patients treated with oral erdafitinib across the clinical trial program. The Oncologist, 31(7). https://doi.org/10.1093/oncolo/oyag174

Vancouver

O'Hagan A, Siefker-Radtke A, Loriot Y, Deprince K, Crow L, Laron M, et al. Incidence and outcomes of FGFR inhibitor-associated retinopathy of patients treated with oral erdafitinib across the clinical trial program. The Oncologist. 2026;31(7). doi:10.1093/oncolo/oyag174

BibTeX
@article{OHagan2026,
  author = {O'Hagan, Anne and Siefker-Radtke, Arlene and Loriot, Yohann and Deprince, Kris and Crow, Lauren and Laron, Michal and Adelman, Ron and Sweiti, Hussein and Triantos, Spyros},
  title = {Incidence and outcomes of FGFR inhibitor-associated retinopathy of patients treated with oral erdafitinib across the clinical trial program},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {7},
  doi = {10.1093/oncolo/oyag174}
}
Kostenlos starten →